Veranstaltungsdetails
DVT risk
- nAPCsr as a new tool for gynecologist
- Thrombotic risk associated with estrogen therapies
- In silico nAPCsr-based model enables personalized risk assessment
- Combined hormonal contraceptives and DVT
- Impact of the progestin
- Impact of the estrogen